価格
  1. 米国企業
  2. Axe Compute Inc.
  3. Raw

Axe Compute Inc.【AGPU】

時価総額
$1438万
PER
腫瘍特異的3DモデルとAIを用いた創薬支援の新興企業。患者由来バイオバンク連携の3D腫瘍モデルとChemoFx等の腫瘍プロファイリングサービスを展開。2025年1月のRenovaroとのLOI、2025年3月にRenovaroが467290株を50万ドルで取得。米国中心に展開。
株価業績
サマリーテーブルに戻る
2011年
12月31日		2012年
12月31日		2013年
12月31日		2014年
12月31日		2015年
12月31日		2016年
12月31日		2017年
12月31日		2018年
12月31日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日		2024年
12月31日
Net loss---------19,390,766-25,884,397-19,657,174-25,737,634-13,983,967-12,664,388
Loss from discontinued operations--------------1,804,183
Net loss from continuing operations--------------10,860,205
Depreciation and amortization----78,56682,35671,562147,628704,8831,024,8481,340,3011,313,075739,316162,079
Amortization of operating lease right-of-use assets-------------533,584
Vesting expense355,124355,124355,124-871,877165,2714,042,2561,124,9282,250,422721,269715,938166,3122,0381,118
Common stock issued for consulting and other---------450,901205,193356,125299,43099,253
(Gain) on derivative instruments--------------1,376
Loss on disposal of property and equipment-----17,0762,387--------803
Loss on disposal of intangible assets--------------4,738
Accounts receivable50,29439,71197,245-39,696-19,26663698,58095,103-143,316-69,91320,769-23,0002,501467,925
Inventories97,605145,209122,175245,192-135,62740,468-7,163-23,979-91,11494,71598,14942,80863,881-95,075
Prepaid expense and other assets30,14827,40960,588129,42781,564-122,943141,329-139,89529,747245,526194,363-78,42543,377-208,776
Accounts payable-----1,544,105-430,301-79,650305,227365,772-1,656,158-350,296-78,322398,575-191,145
Accrued expenses and other678,434222-2,415,967791,459-870,540493,8991,285,678700,966-499,563869,987-397,851-134,961
Contract liabilities-------16,40217,31912,64454,54841,819-293,9822,486
Operating lease liability--------------444,896
Other long-term liabilities-------------18,028
Net cash (used in) continuing operating activities:---3,855,166-3,371,413-7,487,293-4,381,440--------10,974,568
Purchase of property and equipment12,25812,258175,019101,40932,47032,76045,093177,7325,888298,379910,429419,869276,3529,510
Acquisition of intangibles142,495142,495195,85019,82828,09511,98710,17954,27120,71962,39851,89355,82826,019-
Net cash (used in) continuing investing activities:---216,116-121,237-60,565-422,860--------9,510
Proceeds from issuance of common stock and warrants457157,081131,712,1583,814,9382,959,5095,323,0185,057,91950,523,5276,507,050-5
Costs to issue common stock and warrants-------------870,960
Repurchase of common stock upon vesting of restricted stock units----------11,52627,6541,510-
Proceeds from issuance of financing note payable------------364,721275,098
Repayment of note payable------------214,313425,506
Net cash provided by continuing financing activities--113121,712,158-------4
Net cash (used in) operating activities--------------981,103
Net cash provided by (used in) investing activities-------------32,000
Net cash (used in) discontinued operations--------------949,103
Net (decrease) in cash--------604,037-11,321527,50127,524,283-6,131,092-13,342,863-7,993,987
Cash payments for interest--------146,064145,831690,5083,82113,90411,466
Equipment transferred from discontinued operations-------------5,140
Right-of-use assets obtained in exchange for lease liabilities------------3-
Common stock issued------------4,934-